The New England journal of medicine
The most recent articles from:
N. Engl. J. Med.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
A clinical trial that compared erlotinib with a placebo for non-small-cell lung cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from participants in this trial to investigate whether responsiveness to erlotinib and its impact on survival were associated with expression by the tumor of epidermal growth factor receptor (EGFR) and EGFR gene amplification and mutations. ⋯ Among patients with non-small-cell lung cancer who receive erlotinib, the presence of an EGFR mutation may increase responsiveness to the agent, but it is not indicative of a survival benefit.